메뉴 건너뛰기




Volumn 4, Issue 1, 2006, Pages 5-13

Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN; GLUCOCORTICOID; OSTEOCALCIN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; PREDNISONE; RALOXIFENE; TELOPEPTIDE; UNCLASSIFIED DRUG; BONE DENSITY CONSERVATION AGENT;

EID: 33646118014     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-006-0009-2     Document Type: Review
Times cited : (23)

References (56)
  • 1
    • 0037288822 scopus 로고    scopus 로고
    • A comprehensive review of treatments for postmenopausal osteoporosis
    • Hauselmann HJ, Rizzoli R: A comprehensive review of treatments for postmenopausal osteoporosis. Osteoporos Int 2003, 14:2-12.
    • (2003) Osteoporos Int , vol.14 , pp. 2-12
    • Hauselmann, H.J.1    Rizzoli, R.2
  • 2
    • 23744459272 scopus 로고    scopus 로고
    • Postmenopausal osteoporosis
    • Rosen CJ: Postmenopausal osteoporosis. N Engl J Med 2005, 353:595-603.
    • (2005) N Engl J Med , vol.353 , pp. 595-603
    • Rosen, C.J.1
  • 3
    • 0034812187 scopus 로고    scopus 로고
    • Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study
    • Dempster DW, Cosman F, Kurland ES, et al.: Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001, 16:1846-1853.
    • (2001) J Bone Miner Res , vol.16 , pp. 1846-1853
    • Dempster, D.W.1    Cosman, F.2    Kurland, E.S.3
  • 4
    • 21344454577 scopus 로고    scopus 로고
    • Parathyroid hormone and teriparatide for the treatment of osteoporosis; a review of the evidence and suggested guidelines for its use
    • Hodsman AB, Bauer DC, Dempster DW, et al.: Parathyroid hormone and teriparatide for the treatment of osteoporosis; a review of the evidence and suggested guidelines for its use. Endocr Rev 2005, 26:688-703.
    • (2005) Endocr Rev , vol.26 , pp. 688-703
    • Hodsman, A.B.1    Bauer, D.C.2    Dempster, D.W.3
  • 5
    • 0035900949 scopus 로고    scopus 로고
    • Risk of new vertebral fracture in the year following a fracture
    • Lindsay R, Silverman SL, Cooper C, et al.: Risk of new vertebral fracture in the year following a fracture. JAMA 2001, 285:320-323.
    • (2001) JAMA , vol.285 , pp. 320-323
    • Lindsay, R.1    Silverman, S.L.2    Cooper, C.3
  • 6
    • 0035837553 scopus 로고    scopus 로고
    • Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
    • Neer RM, Arnaud CD, Zanchetta JR, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441. This pivotal clinical trial establishes the efficacy of teriparatide in reducing vertebral and nonvertebral fracture incidence in postmenopausal women with osteoporosis.
    • (2001) N Engl J Med , vol.344 , pp. 1434-1441
    • Neer, R.M.1    Arnaud, C.D.2    Zanchetta, J.R.3
  • 7
    • 18644374464 scopus 로고    scopus 로고
    • A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis
    • Body JJ, Gaich GA, Scheele WH, et al.: A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002, 87:4528-4535.
    • (2002) J Clin Endocrinol Metab , vol.87 , pp. 4528-4535
    • Body, J.J.1    Gaich, G.A.2    Scheele, W.H.3
  • 8
    • 24144443783 scopus 로고    scopus 로고
    • Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment
    • Prince R, Sipos A, Hossain A, et al.: Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 2005, 20:1507-1513.
    • (2005) J Bone Miner Res , vol.20 , pp. 1507-1513
    • Prince, R.1    Sipos, A.2    Hossain, A.3
  • 9
    • 15944389876 scopus 로고    scopus 로고
    • Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures
    • Gallagher JC, Genant HK, Crans GG, et al.: Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab 2005, 90:1583-1587.
    • (2005) J Clin Endocrinol Metab , vol.90 , pp. 1583-1587
    • Gallagher, J.C.1    Genant, H.K.2    Crans, G.G.3
  • 10
    • 0037216436 scopus 로고    scopus 로고
    • The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis
    • Marcus R, Wang O, Satterwhite J, Mitlak B: The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2003, 18:18-23.
    • (2003) J Bone Miner Res , vol.18 , pp. 18-23
    • Marcus, R.1    Wang, O.2    Satterwhite, J.3    Mitlak, B.4
  • 11
    • 0033710488 scopus 로고    scopus 로고
    • Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers
    • Kurland ES, Cosman F, McMahon DJ, et al.: Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000, 85:3069-3076. This publication represents the first clinical trial of teriparatide in men with osteoporosis demonstrating its actions to increase bone density and providing an experimental basis to the concept of the anabolic window.
    • (2000) J Clin Endocrinol Metab , vol.85 , pp. 3069-3076
    • Kurland, E.S.1    Cosman, F.2    McMahon, D.J.3
  • 12
    • 0037214255 scopus 로고    scopus 로고
    • The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis
    • Orwoll ES, Scheele WH, Paul S, et al.: The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003, 18:9-17. The largest clinical trial to date on the use of teriparatide in men with osteoporosis. With a larger number of subjects than employed in the report of Kurland et al. [11], this paper helps to document the efficacy of teriparatide in men with idiopathic osteoporosis or in those with hypogonadism.
    • (2003) J Bone Miner Res , vol.18 , pp. 9-17
    • Orwoll, E.S.1    Scheele, W.H.2    Paul, S.3
  • 13
    • 22844447275 scopus 로고    scopus 로고
    • Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: Treatment and discontinuation of therapy
    • Kaufman JM, Orwoll E, Goemaere S, et al.: Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 2005, 16:510-516.
    • (2005) Osteoporos Int , vol.16 , pp. 510-516
    • Kaufman, J.M.1    Orwoll, E.2    Goemaere, S.3
  • 14
    • 28144446799 scopus 로고    scopus 로고
    • Parathyroid hormone as an anabolic skeletal therapy
    • Rubin MR, Bilezikian JP: Parathyroid hormone as an anabolic skeletal therapy. Drugs 2005, 65:2481-2498.
    • (2005) Drugs , vol.65 , pp. 2481-2498
    • Rubin, M.R.1    Bilezikian, J.P.2
  • 15
    • 19044364417 scopus 로고    scopus 로고
    • Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis
    • Chen P, Satterwhite JH, Licata AA, et al.: Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005, 20:962-970.
    • (2005) J Bone Miner Res , vol.20 , pp. 962-970
    • Chen, P.1    Satterwhite, J.H.2    Licata, A.A.3
  • 16
    • 23044456161 scopus 로고    scopus 로고
    • Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy
    • Dobnig H, Sipos A, Jiang Y, et al.: Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 2005, 90:3970-3977.
    • (2005) J Clin Endocrinol Metab , vol.90 , pp. 3970-3977
    • Dobnig, H.1    Sipos, A.2    Jiang, Y.3
  • 17
    • 0345305666 scopus 로고    scopus 로고
    • Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis
    • Hodsman AB, Hanley DA, Ettinger MP, et al.: Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 2003, 88:5212-5220.
    • (2003) J Clin Endocrinol Metab , vol.88 , pp. 5212-5220
    • Hodsman, A.B.1    Hanley, D.A.2    Ettinger, M.P.3
  • 18
    • 33646807061 scopus 로고    scopus 로고
    • Preventing the first vertebral fracture in postmenopausal women with low bone mass using PTH(1-84): Results from the TOP Study
    • Greenspan SL, Bone HG, Marriott TB, et al.: Preventing the first vertebral fracture in postmenopausal women with low bone mass using PTH(1-84): results from the TOP Study. J Bone Miner Res 2005, 20(Suppl 1):S56.
    • (2005) J Bone Miner Res , vol.20 , Issue.SUPPL. 1
    • Greenspan, S.L.1    Bone, H.G.2    Marriott, T.B.3
  • 19
    • 0242413030 scopus 로고    scopus 로고
    • Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure
    • Jiang Y, Zhao JJ, Mitlak BH, et al.: Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003, 18:1932-1941.
    • (2003) J Bone Miner Res , vol.18 , pp. 1932-1941
    • Jiang, Y.1    Zhao, J.J.2    Mitlak, B.H.3
  • 20
    • 23044465001 scopus 로고    scopus 로고
    • Treatment of osteoporotic women with parathyroid hormone 1-84 for 18 months improves cancellous bone formation and structure; a bone biopsy study
    • Recker R, Bare S, Miller M, et al.: Treatment of osteoporotic women with parathyroid hormone 1-84 for 18 months improves cancellous bone formation and structure; a bone biopsy study. J Bone Miner Res 2004, 19(Supp 1):S97.
    • (2004) J Bone Miner Res , vol.19 , Issue.SUPPL. 1
    • Recker, R.1    Bare, S.2    Miller, M.3
  • 21
    • 0035158179 scopus 로고    scopus 로고
    • Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys
    • Burr DB, Hirano T, Turner CH, et al.: Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 2001, 16:157-165.
    • (2001) J Bone Miner Res , vol.16 , pp. 157-165
    • Burr, D.B.1    Hirano, T.2    Turner, C.H.3
  • 22
    • 0037369113 scopus 로고    scopus 로고
    • Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis
    • Zanchetta JR, Bogado CE, Ferretti JL, et al.: Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 2003, 18:539-543.
    • (2003) J Bone Miner Res , vol.18 , pp. 539-543
    • Zanchetta, J.R.1    Bogado, C.E.2    Ferretti, J.L.3
  • 23
    • 0033926149 scopus 로고    scopus 로고
    • Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis
    • Hodsman AB, Kisiel M, Adachi JD, et al.: Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis. Bone 2000, 27:311-318.
    • (2000) Bone , vol.27 , pp. 311-318
    • Hodsman, A.B.1    Kisiel, M.2    Adachi, J.D.3
  • 24
    • 0035051721 scopus 로고    scopus 로고
    • Effects of human parathyroid hormone (1-34), LY333334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbits
    • Mashiba T, Burr DB, Turner CH, et al.: Effects of human parathyroid hormone (1-34), LY333334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbits. Bone 2001, 28:538-547.
    • (2001) Bone , vol.28 , pp. 538-547
    • Mashiba, T.1    Burr, D.B.2    Turner, C.H.3
  • 25
    • 0030804947 scopus 로고    scopus 로고
    • Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis
    • Lindsay R, Nieves J, Formica C, et al.: Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997, 350:550-555.
    • (1997) Lancet , vol.350 , pp. 550-555
    • Lindsay, R.1    Nieves, J.2    Formica, C.3
  • 26
    • 0035063315 scopus 로고    scopus 로고
    • Parathyroid hormone added to established hormone therapy: Effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal
    • Cosman F, Nieves J, Woelfert L, et al.: Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001, 16:925-931.
    • (2001) J Bone Miner Res , vol.16 , pp. 925-931
    • Cosman, F.1    Nieves, J.2    Woelfert, L.3
  • 27
    • 0001401316 scopus 로고    scopus 로고
    • Parathyroid hormone 1-34 (hPTH 1-34) and estrogen produce dramatic bone density increases in postmenopausal osteoporosis-results from a placebo-controlled randomized trial
    • Roe E, Sanchez S, del Puerto G, et al.: Parathyroid hormone 1-34 (hPTH 1-34) and estrogen produce dramatic bone density increases in postmenopausal osteoporosis-results from a placebo-controlled randomized trial. J Bone Miner Res 1999, 14(Suppl 1):S137.
    • (1999) J Bone Miner Res , vol.14 , Issue.SUPPL. 1
    • Roe, E.1    Sanchez, S.2    Del Puerto, G.3
  • 28
    • 3242762388 scopus 로고    scopus 로고
    • Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate
    • Ettinger B, San Martin J, Crans G, Pavo I: Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004, 19:745-751. A widely quoted article addressing an important issue, namely whether previous antiresorptive therapy affects the subsequent densitometric response to teriparatide. This paper led to the concept that marked suppression of bone turnover by antiresorptive therapy can lead to a delay in the densitometric response to teriparatide.
    • (2004) J Bone Miner Res , vol.19 , pp. 745-751
    • Ettinger, B.1    San Martin, J.2    Crans, G.3    Pavo, I.4
  • 29
    • 23444435838 scopus 로고    scopus 로고
    • Daily and cyclic parathyroid hormone in women receiving alendronate
    • Cosman F, Nieves J, Zion M, et al.: Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 2005, 353:566-575. In this paper, the authors present an interesting new way to administer teriparatide. They compared the effects of a cyclical 3- month regimen with continuous teriparatide therapy over a 15 month period. In addition to showing that bone density improves to the same extent with either approach, they provide intriguing new possibility that this approach expands the anabolic window.
    • (2005) N Engl J Med , vol.353 , pp. 566-575
    • Cosman, F.1    Nieves, J.2    Zion, M.3
  • 30
    • 0036736811 scopus 로고    scopus 로고
    • Clinical review 151: The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: A re-examination of the evidence
    • Rubin MR, Bilezikian JP: Clinical review 151: the role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence. J Clin Endocrinol Metab 2002, 87:4033-4041.
    • (2002) J Clin Endocrinol Metab , vol.87 , pp. 4033-4041
    • Rubin, M.R.1    Bilezikian, J.P.2
  • 31
    • 0032532062 scopus 로고    scopus 로고
    • Results of a randomized controlled clinical trial
    • Lane NE, Sanchez S, Modin GW, et al.: Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998, 102:1627-1633.
    • (1998) J Clin Invest , vol.102 , pp. 1627-1633
    • Lane, N.E.1    Sanchez, S.2    Modin, G.W.3
  • 32
    • 0141684971 scopus 로고    scopus 로고
    • The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis
    • Black DM, Greenspan SL, Ensrud KE, et al.: The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349:1207-1215. A seminal paper showing that combination therapy with PTH and alendronate does not provide for greater gains in bone density than PTH alone.
    • (2003) N Engl J Med , vol.349 , pp. 1207-1215
    • Black, D.M.1    Greenspan, S.L.2    Ensrud, K.E.3
  • 33
    • 0141796739 scopus 로고    scopus 로고
    • The effects of parathyroid hormone, alendronate, or both in men with osteoporosis
    • Finkelstein JS, Hayes A, Hunzelman JL, et al.: The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003, 349:1216-1226. Similar to the results of Black et al. [32], this paper shows similar results when a group of men with osteoporosis were studied with combination antiresorptive and anabolic therapy.
    • (2003) N Engl J Med , vol.349 , pp. 1216-1226
    • Finkelstein, J.S.1    Hayes, A.2    Hunzelman, J.L.3
  • 34
    • 28144432215 scopus 로고    scopus 로고
    • Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis; results from a 6-month double-blind placebo-controlled trial
    • Deal C, Omizo M, Schwartz EN, et al.: Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis; results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 2004, 19 (Supp 1):1169.
    • (2004) J Bone Miner Res , vol.19 , Issue.SUPPL. 1 , pp. 1169
    • Deal, C.1    Omizo, M.2    Schwartz, E.N.3
  • 35
    • 6344278780 scopus 로고    scopus 로고
    • Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopasual women with osteoporosis
    • Lindsay R, Scheele WH, Neer R, et al.: Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopasual women with osteoporosis. Arch Intern Med 2004, 164:2024-2030.
    • (2004) Arch Intern Med , vol.164 , pp. 2024-2030
    • Lindsay, R.1    Scheele, W.H.2    Neer, R.3
  • 36
    • 0034458020 scopus 로고    scopus 로고
    • Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate
    • see comments
    • Rittmaster RS, Bolognese M, Ettinger MP, et al.: Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate [see comments]. J Clin Endocrinol Metab 2000, 85:2129-2134.
    • (2000) J Clin Endocrinol Metab , vol.85 , pp. 2129-2134
    • Rittmaster, R.S.1    Bolognese, M.2    Ettinger, M.P.3
  • 37
    • 0034054290 scopus 로고    scopus 로고
    • Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: Results of a randomized controlled clinical trial
    • Lane NE, Sanchez S, Modin GW, et al.: Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 2000, 15:944-951.
    • (2000) J Bone Miner Res , vol.15 , pp. 944-951
    • Lane, N.E.1    Sanchez, S.2    Modin, G.W.3
  • 38
    • 4544266340 scopus 로고    scopus 로고
    • The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]
    • Kurland ES, Heller SL, Diamond B, et al.: The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int 2004, 15:992-997.
    • (2004) Osteoporos Int , vol.15 , pp. 992-997
    • Kurland, E.S.1    Heller, S.L.2    Diamond, B.3
  • 39
    • 23444452077 scopus 로고    scopus 로고
    • The effect of one year of alendronate following one year of PTH1-84: Second year results from the PTH and alendronate (PaTH) trial
    • Black DM, Bilezikian JP, Rosen C, et al.: The effect of one year of alendronate following one year of PTH1-84: second year results from the PTH and alendronate (PaTH) trial. N Engl J Med 2005, 353:555-566. This second PaTH paper provides data in a rigorously controlled trial that argues for the importance of antiresorptive therapy after anabolic skeletal therapy. The results show that when PTH is not followed up by alendronate, major losses in bone density, as measured by DXA or by QCT, are experienced. When alendronate is used after PTH, the gains in bone density are maintained or further enhanced.
    • (2005) N Engl J Med , vol.353 , pp. 555-566
    • Black, D.M.1    Bilezikian, J.P.2    Rosen, C.3
  • 40
    • 0037341832 scopus 로고    scopus 로고
    • Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: A paired study before and after treatment
    • Misof BM, Roschger P, Cosman F, et al.: Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab 2003, 88:1150-1156.
    • (2003) J Clin Endocrinol Metab , vol.88 , pp. 1150-1156
    • Misof, B.M.1    Roschger, P.2    Cosman, F.3
  • 41
    • 0033345813 scopus 로고    scopus 로고
    • On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism
    • Dempster DW, Parisien M, Silverberg SJ, et al.: On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab 1999, 84:1562-1566.
    • (1999) J Clin Endocrinol Metab , vol.84 , pp. 1562-1566
    • Dempster, D.W.1    Parisien, M.2    Silverberg, S.J.3
  • 42
    • 3242887547 scopus 로고    scopus 로고
    • Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose
    • Vahle JL, Long GG, Sandusky G, et al.: Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 2004, 32:426-438.
    • (2004) Toxicol Pathol , vol.32 , pp. 426-438
    • Vahle, J.L.1    Long, G.G.2    Sandusky, G.3
  • 43
    • 33646795236 scopus 로고    scopus 로고
    • No observable carcinogenic effect dose level identified in Fischer 344 rats following daily treatment with PTH(1-84) for 2 years: Role of the C-terminal PTH receptor?
    • Wilker C, Jolette J, Smith S, et al.: No observable carcinogenic effect dose level identified in Fischer 344 rats following daily treatment with PTH(1-84) for 2 years: role of the C-terminal PTH receptor? J Bone Miner Res 2004, 19(Supp 1):SA435.
    • (2004) J Bone Miner Res , vol.19 , Issue.SUPPL. 1
    • Wilker, C.1    Jolette, J.2    Smith, S.3
  • 44
    • 0035991225 scopus 로고    scopus 로고
    • Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women
    • Tashjian AH, Chabner BA: Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women. J Bone Miner Res 2002, 17:1151-1161.
    • (2002) J Bone Miner Res , vol.17 , pp. 1151-1161
    • Tashjian, A.H.1    Chabner, B.A.2
  • 45
    • 0037207667 scopus 로고    scopus 로고
    • Vassilopoulou-sellin, osteosarcoma of bone in apatient with primary hyperparathyroidism: A case report
    • Betancourt M, Wirfel KL, Raymond AK, et al.: Vassilopoulou-sellin, osteosarcoma of bone in apatient with primary hyperparathyroidism: a case report. J Bone Miner Res 2003, 18:163-166.
    • (2003) J Bone Miner Res , vol.18 , pp. 163-166
    • Betancourt, M.1    Wirfel, K.L.2    Raymond, A.K.3
  • 46
    • 0015189570 scopus 로고
    • Hyperparathyroidism with multiple malignant tumours of bone with giant-cells. A case report
    • Wiig JN, Bakken TS: Hyperparathyroidism with multiple malignant tumours of bone with giant-cells. A case report. Acta Chir Scand 1971, 137:391-393.
    • (1971) Acta Chir Scand , vol.137 , pp. 391-393
    • Wiig, J.N.1    Bakken, T.S.2
  • 47
    • 0031045671 scopus 로고    scopus 로고
    • Hyperparathyroidism associated with sarcoma of bone
    • Smith J, Huvos AG, Chapman M, et al.: Hyperparathyroidism associated with sarcoma of bone. Skeletal Radiol 1997, 26:107-112.
    • (1997) Skeletal Radiol , vol.26 , pp. 107-112
    • Smith, J.1    Huvos, A.G.2    Chapman, M.3
  • 48
    • 0023949389 scopus 로고
    • Increased risk of malignant diseases after surgery for primary hyperparathyroidism. A nationwide cohort study
    • Palmer M, Adami HO, Krusemo UB, Ljunghall S: Increased risk of malignant diseases after surgery for primary hyperparathyroidism. A nationwide cohort study. Am J Epidemiol 1988, 127:1031-1040.
    • (1988) Am J Epidemiol , vol.127 , pp. 1031-1040
    • Palmer, M.1    Adami, H.O.2    Krusemo, U.B.3    Ljunghall, S.4
  • 49
    • 24144465673 scopus 로고    scopus 로고
    • Primary hyperparathyroidism and osteosarcoma: Examination of a large cohort identifies three cases of fibroblastic osteosarcoma
    • Jiminez C, Yang Y, Kim HW, et al.: Primary hyperparathyroidism and osteosarcoma: examination of a large cohort identifies three cases of fibroblastic osteosarcoma. J Bone Miner Res 2005, 20:1562-1568.
    • (2005) J Bone Miner Res , vol.20 , pp. 1562-1568
    • Jiminez, C.1    Yang, Y.2    Kim, H.W.3
  • 50
    • 17144372762 scopus 로고    scopus 로고
    • Administration of ThPTH to humans using Macroflux transdermal technology results in the rapid delivery of biologically active PTH
    • Gopalakrishnan V, Hwang S, Loughre H, et al.: Administration of ThPTH to humans using Macroflux transdermal technology results in the rapid delivery of biologically active PTH. J Bone Miner Res 2004, 19(Supp 1):M484.
    • (2004) J Bone Miner Res , vol.19 , Issue.SUPPL. 1
    • Gopalakrishnan, V.1    Hwang, S.2    Loughre, H.3
  • 51
    • 0034865283 scopus 로고    scopus 로고
    • Oral delivery of biologically active parathyroid hormone
    • Leone-Bay A, Sato M, Paton D, et al.: Oral delivery of biologically active parathyroid hormone. Pharm Res 2001, 18:964-970.
    • (2001) Pharm Res , vol.18 , pp. 964-970
    • Leone-Bay, A.1    Sato, M.2    Paton, D.3
  • 52
    • 0033329305 scopus 로고    scopus 로고
    • Comparison of the biochemical responses to human parathyroid hormone-(1-31)NH2 and hPTH-(1-34) in healthy humans
    • Fraher LJ, Avram R, Watson PH, et al.: Comparison of the biochemical responses to human parathyroid hormone-(1-31)NH2 and hPTH-(1-34) in healthy humans. J Clin Endocrinol Metab 1999, 84:2739-2743.
    • (1999) J Clin Endocrinol Metab , vol.84 , pp. 2739-2743
    • Fraher, L.J.1    Avram, R.2    Watson, P.H.3
  • 53
    • 0037323386 scopus 로고    scopus 로고
    • Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis
    • Horwitz MJ, Tedesco MB, Gundberg C, et al.: Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2003, 88:569-575.
    • (2003) J Clin Endocrinol Metab , vol.88 , pp. 569-575
    • Horwitz, M.J.1    Tedesco, M.B.2    Gundberg, C.3
  • 54
    • 28144453440 scopus 로고    scopus 로고
    • Parsimony with PTH: Is a single weekly injection of PTH superior to a larger cumulative dose given daily?
    • Black DM, Rosen CJ: Parsimony with PTH: Is a single weekly injection of PTH superior to a larger cumulative dose given daily? J Bone Miner Res 2002, 17(Suppl 1):SA367.
    • (2002) J Bone Miner Res , vol.17 , Issue.SUPPL. 1
    • Black, D.M.1    Rosen, C.J.2
  • 55
    • 23444450743 scopus 로고    scopus 로고
    • Combination and sequential therapy for osteoporosis
    • Heaney RP, Recker RR: Combination and sequential therapy for osteoporosis. N Engl J Med 2005, 353:624-625.
    • (2005) N Engl J Med , vol.353 , pp. 624-625
    • Heaney, R.P.1    Recker, R.R.2
  • 56
    • 0034123554 scopus 로고    scopus 로고
    • Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats
    • Gowen M, Stroup GB, Dodds RA, et al.: Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest 2000, 105:1595-1604.
    • (2000) J Clin Invest , vol.105 , pp. 1595-1604
    • Gowen, M.1    Stroup, G.B.2    Dodds, R.A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.